BIAS NOTICE

Encode may hold positions in covered names, may have current or past compensated relationships, and may be pursuing such relationships. Assume bias. See encodelp.com/disclosure for specifics.

Delcath Systems: Filtering Through Its Past & Future

By Hogan Mullally & Ryan Aldridge • October 25, 2021 • Coverage Universe

An interview with Gerard Michel, CEO of Delcath Systems, where Gerard reflects back on his time with Vericel, the decision to become CEO of Delcath, the initial NDA submission for the HEPZATO™ KIT, and the preliminary data release from the Phase 3 FOCUS study. Gerard also addresses the future for Delcath, including the impending full Phase 3 FOCUS results, future clinical indications to be pursued with the HEPZATO™ KIT, and commercial dynamics in the interventional oncology space.

To listen on Podbean click here

Apple Podcasts here

Spotify here

YouTube here

 

IMPORTANT - ASSUME BIAS

Treat what you read here as biased. Encode Ideas, LP and its principals may hold positions in any company covered, may have current or past compensated relationships with covered companies, and may be pursuing such relationships. Our analysis is influenced by all of the above - actual positions, current relationships, past relationships, and prospective relationships. Assume errors. Nothing herein is investment advice. See encodelp.com/disclosure for current and past sponsor relationships.

Authors: Hogan Mullally, Ryan Aldridge • Encode Ideas, LP